Abac’s precision platform
How Abac’s pathogen-specific approach could reduce emergence of antibiotic resistance
Abac Therapeutics S.A. is taking a precision approach to treat bacterial infections that could avoid the development of drug resistance that plagues broad-spectrum antibiotics.
The company’s PasNas platform uses phenotypic and in vitro assays to screen chemical libraries and identify pathogen-specific antibiotics for multidrug resistant microbes. According to CSO Domingo Gargallo-Viola, PasNas can identify candidates for any infectious microbial